4536 — Santen Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapSuper Stock

Annual income statement for Santen Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2019 March 31st	2020 March 31st	R2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	234,026	241,555	249,605	266,257	279,037
Cost of Revenue
Gross Profit	143,262	146,724	151,384	156,586	166,087
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	190,386	209,169	237,410	228,890	282,425
Operating Profit	43,640	32,386	12,195	37,367	-3,388
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	43,117	32,091	11,688	35,616	-5,799
Provision for Income Taxes
Net Income After Taxes	31,943	21,714	9,126	27,189	-14,983
Minority Interest
Net Income Before Extraordinary Items
Net Income	31,954	23,618	9,311	27,218	-14,948
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	31,955	23,620	9,311	27,218	-14,955
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	74.3	71.6	72.7	65.3	26.3
Dividends per Share